A systematic review of side effects of nucleoside and nucleotide drugs used for treatment of chronic hepatitis B

被引：42
作者：
Khungar V. [1 ]
Han S.-H. [1 ,2 ]
机构：
[1] Division of Digestive Diseases, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA
[2] Pfleger Liver Institute, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA 90095
来源：
Current Hepatitis Reports | 2010年 / 9卷 / 2期
关键词：
Adefovir dipivoxil; Chronic hepatitis B virus infection; Entecavir; Lamivudine; Nucleosides; Nucleotides; Telbivudine; Tenofovir disoproxil fumarate;
D O I：
10.1007/s11901-010-0039-1
中图分类号：
学科分类号：
摘要：
Although nucleosides and nucleotides have a good safety record for the treatment of hepatitis B, there have been no systematic reviews on this topic. We searched Medline to include studies of the oral antiviral agents for hepatitis B and adverse events, with at least 48 weeks of follow-up from the initiation of treatment with the drug. Important toxicities include nephrotoxicity, myopathy, and resistance. It is often difficult to ascertain whether an adverse effect is from the study drug or the natural progression of the disease. Further safety data are needed for the newer agents and for all agents with regard to patients with decompensated liver disease, renal dysfunction, the elderly, children, and pregnant women. © 2010 The Author(s).
引用
收藏
页码：75 / 90
页数：15
相关论文
共 47 条
  • [21] May 30-June 4, 2009.
  • [22] Schiff E., Simsek H., Lee W.M., Et al., Efficacy and safety of entecavir in patients with chronic hepatitis B and advanced hepatic fibrosis or cirrhosis, Am J Gastroenterol, 103, pp. 2776-2783, (2008)
  • [23] Lai C.L., Leung N., Teo E.K., Et al., A 1-year trial of telbivudine, lamivudine, and the combination in patients with hepatitis B e antigen-positive chronic hepatitis B, Gastroenterology, 129, pp. 528-536, (2005)
  • [24] Lai C.L., Gane E., Liaw Y.F., Et al., Telbivudine versus lamivudine in patients with chronic hepatitis B, N Engl J Med, 357, pp. 2576-2588, (2007)
  • [25] Liaw Y.F., Gane E., Leung N., Et al., 2-Year GLOBE trial results: Telbivudine is superior to lamivudine in patients with chronic hepatitis B, Gastroenterology, 136, pp. 486-495, (2009)
  • [26] Zhang X.S., Jin R., Zhang S.B., Et al., Clinical features of adverse reactions associated with telbivudine, World J Gastroenterol, 14, pp. 3549-3553, (2008)
  • [27] Leemans W.F., Hla J., Hgm N., Et al., Switching patients with lamivudine resistant chronic hepatitis B virus from tenofovir to adefovir results in less potent HBV-DNA suppression, J Viral Hepat, 15, pp. 108-114, (2008)
  • [28] Marcellin P., Heathcoate E.J., Buti M., Et al., Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B, N Engl J Med, 359, pp. 2442-2455, (2008)
  • [29] Tan L.K.K., Gilleece Y., Mandalia S., Reduced glomerular filtration rate but sustained virologic response in HIV/hepatitis B co-infected individuals on long-term tenofovir, Journal of Viral Hepatitis, 16, pp. 471-478, (2009)
  • [30] Jjy S., Lai J.K., Zeuzem S., Et al., Lamivudine compared with lamivudine and adefovir dipivoxil for the treatment of HBeAg-positive chronic hepatitis B, J Hepatol, pp. 728-735, (2008)
12345